SERVICES PROVIDED TO YOU BY: Transvac, VetBioNet & Instruct
Vaccine development requires a combination of specialized skills and technical capacities not readily available at a single organization. Find all those skills and capacities in our catalogue.
Please note that all in vivo models for studying immunogenicity, adjuvants or vaccine efficacy are available in the IN VIVO MODELS catalogue of services.
The services listed below are available for access regardless of the call for proposals and research topic you select in your pre-application form. When applicable, viral-like particles and/or pseudoviruses are used as study models for pathogens of interest.
VACCINE PLATFORM TECHNOLOGIES: SCREENING, EXPRESSION AND OPTIMISATION
Provided to you by: Transvac & VetBioNet
Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu
William MARTIN
William.Martin@euvaccine.eu
- Cross-platform screening and pre‑clinical optimization with access to vaccine platform technologies (including proteins, viral like particles, viral vectors) and expression systems (including mammalian and insect cells)
Small-to-medium-scale (mg-scale) expression and purification of antigens from multiple candidate constructs. Expression can be compared in multiple expression systems, including P. pastoris, L. lactis, E. coli; Nicotiana; and constitutive/transient expression in mammalian/ insect cells. Vaccine formats include design and production of viral vector vaccines, Adenovirus (human and chimpanzee) and MVA - Custom construction of nanoparticles based on respiratory syncytial virus nucleoprotein as booster for antigen presentation
- Custom construction of recombinant viral proteins in HEK Freestyle cells
- Custom construction of recombinant vaccine
Two available backbones (non-deleted or E1-deleted genomes) derived from the Manhattan vaccine strain of the canine adenovirus type 2 (CAV-2) - Design and development of nanoparticle-based mucosal vaccine systems for SARS-CoV-2 or other respiratory pathogens
- Expression and purification of SARS-CoV structural proteins for vaccination and in vitro diagnostics
Expression systems available: E. coli, baculovirus
VACCINE PROCESS DEVELOPMENT & PRODUCTION
Provided to you by: Transvac*
Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu
William MARTIN
William.Martin@euvaccine.eu
- Pre‑clinical GLP production services
- Development and implementation of analytical methods for product characterization and process control and monitoring
- GMP manufacturing of starting materials
- GMP manufacturing of clinical materials
*Please note that ISIDORe funding may be limited for high cost GLP and GMP services, but might be provided as paid-for service
VACCINE ADJUVANTS & FORMULATION
Provided to you by: Transvac
Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu
William MARTIN
William.Martin@euvaccine.eu
- Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b
- Provision of CAF01 and CAF09b adjuvants at GMP grade for use in clinical studies
- Development and characterisation of vaccine formulations with adjuvants SWE, SQ, and SMQ and liposome adjuvants LQ and LMQ
- Upscaling of emulsion adjuvants (SQ, SMQ) and liposome adjuvants (LQ, LMQ) from lab-scale to pilot-scale prior to tech-transferto CDMO for GMP production
- Provision of SWE emulsion adjuvant at GMP grade for use in clinical studies
- Formulation and characterisation of vaccine candidates paired with mucosal or parenteral adjuvants.
STRUCTURAL & CHEMICAL CHARACTERIZATION OF VACCINES AND VACCINE ANTIGENS
Provided to you by: Instruct & the Joint Research Centre of the European Commission
Contact
Pauline AUDERGON
pauline@instruct-eric.org
- Structural characterisation of vaccine antigens (bound or unbound) – see also ANALYTICAL SERVICES
- X-ray methods
- From Sample to X-ray diffraction pipelines
- XChem Fragment Screening
- Online crystallography pipeline for Rapid structural characterization of antigens based on CrystalDirect technology
- Bio-SAXS, solution
- NMR technologies, solid state
- Atomic level characterization and/or interactions (IDP, proteins, host’s proteins, nucleic acids, etc);
- Quality assurance via NMR (HOS of vaccines, antibodies, antigens/adjuvants);
- Fast fingerprinting/profiling via NMR metabolomics on blood (serum, plasma) and urine
- Fragment-screening by NMR
- Cryo-EM (single particle analysis)
- Scanning electron microscopy (SEM) -Transmission electron microscopy (TEM)
- Cryogenic electron microscopy (Cryo-EM)
- Electron tomography
- Cryo-ET (in combination with EuBi for correlative EM/light microscopy)
- X-ray methods
- Physico-chemical and in-vitro characterization of adjuvant and nanovaccines (such as LNP-mRNA)
Physical attributes (size distribution, particle concentration). Chemical (composition, free/bound cargo; cargo release kinetic); Stability (aggregation, time stability; mRNA/antigen integrity). In vitro toxicity (endotoxin contamination, cytotoxicity, immunotoxicity) - Identification and measurement of key quality attributes of nanovaccines